exalt
© exalt

Austria

exalt

  • 2026
  • Speaker
  • Venture

exalt® develops fScreen, a functional diagnostic platform that identifies the most effective cancer treatment for each patient within 72 hours — by directly testing tumor cells against 140+ approved drugs. Validated in two prospective clinical trials, including a Roche-funded randomized study, fScreen launches in 2027 with Europe's leading leukemia laboratory.